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Introduction: Exhaled nitric oxide (NO) is an established technique for monitoring
airway inflammation. We have compared exhaled NO measurements from 3 different
analysers; Ecomedics (E), Niox (N) and Logan (L).
Methods: Thirty subjects (10 non-smoking healthy subjects, 10 non-smoking
patients with asthma and 10 ex-smoking COPD patients) performed 3 repeated
measurements of exhaled NO at a flow rate of 50ml/s on each of the 3 analysers.
Within analyser variability was determined by calculating the repeatability
coefficient for each analyser. Differences between analysers were assessed by
(1) the differences between group means and (2) the Bland Altman method to
estimate the variability expected for an individual using the 3 analysers.
Results: The repeatability coefficients (expressed as ratios) were 1.12, 1.19 and
1.19 for N, E and L, respectively. There were significant differences ðPo0:05Þ
between analysers; the Logan analyser gave the highest group mean values and
Ecomedics gave the lowest group mean values. Differences between analysers were
observed in all subject groups (healthy, asthma, COPD). Similar results were
obtained in the 3 groups when analysed separately. Bland Altman analysis gave the
following ratios [data are mean ratio (95% limits of agreement)]; N:E 1.59
(1.02–2.50), L:N 1.23 (0.72–2.13), L:E 1.96 (1.09–3.57).Published by Elsevier Ltd.
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Table 1 Subject demograph
as mean (SD)).
Asthma C
Age (years) 42.6 (14.6) 6
Sex (M/F) 7M/3F 7
FEV1
(% predicted)
81.4 (19.7) 6
A comparison of three exhaled nitric oxide analysers 1393Conclusion: Our findings indicate that exhaled NO measurements in healthy
subjects and patients with airways disease differ according to the type of analyser
used.
& 2005 Published by Elsevier Ltd.Introduction
The measurement of nitric oxide (NO) in exhaled
breath provides a non-invasive means of assessing
airway inflammation. Exhaled NO levels are raised
in asthma and unstable chronic obstructive pul-
monary disease (COPD) patients.1–3 Studies have
shown that exhaled NO may be used to diagnose
asthma4 and to evaluate the anti-inflammatory
effects of inhaled corticosteroids in patients with
asthma.5
Recommendations for the measurement of ex-
haled NO in clinical practice have enabled stan-
dardisation of the measurement procedure in
different centres.6 However, there are now several
manufacturers of NO analysers. Consequently,
reports of NO measurements have often used
different equipment.1–4 We hypothesised that
although the procedure of exhaled NO measure-
ment has been standardised, there may be differ-
ences due to the analysis equipment used. We
therefore investigated whether there were any
differences in exhaled NO measurements from
healthy subjects, asthmatics and COPD patients
using 3 different commercially available analysers.
NO measurements were performed according to the
manufacturers’ instructions. This replicated the
use of the different analysers in current practice as
closely as possible.Methods
Thirty subjects participated in the study; 10
patients with asthma, 10 patients with COPD and
10 healthy volunteers (Table 1). COPD was definedics (data expressed
OPD Healthy
5.6 (6.7) 32.2 (7.6)
M/3F 5M/5F
3.5 (7.9) 99.5 (9.2)according to the British Thoracic Society guide-
lines.7 All COPD patients were required to be ex-
smokers and 5 were taking regular inhaled corti-
costeroids. All asthma patients and healthy volun-
teers were lifetime non-smokers, and were not
taking inhaled corticosteroids. Subjects were ex-
cluded if they had experienced a respiratory tract
infection in the last 4 weeks. Written informed
consent was obtained and the local ethics commit-
tee approved the study. The study was undertaken
according to the principles of the Declaration of
Helsinki 1975.8
Three NO analysers were used in this study;
Ecomedics AG analyser CLD 88 (Ecomedics; Durn-
ten, Switzerland), Niox (Aerocrine; Solna, Sweden)
and Logan model LR2149 (Logan Research; Roche-
ster, Kent, UK). Each analyser was calibrated
according to the manufacturer’s instructions. The
Niox analyser was calibrated with gas containing NO
at 200 ppb (Hoek Loos BV, Amsterdam, The Nether-
lands). The Ecomedics analyser was calibrated
using source gas containing NO at 20 ppm
(SIT Analytical, Sandwich, UK) which underwent
dilution to a final concentration of 200 ppb. The
Logan analyser was calibrated using gas containing
NO at 100 ppb (BOC, Guildford, UK). After calibra-
tion, gas containing NO at 100 ppb (BOC, Guildford,
UK) was passed through the sample port of each
analyser at a flow rate of 50ml/s, in order to check
that there were no differences between analysers
in the measurement of an externally standardised
source of NO. Each analyser consistently gave a NO
measurement of 100 ppb.
Subjects performed exhaled NO measurements
using each of the 3 machines in random order using
a computer generated randomisation sequence.
These measurements were completed within 1 h on
the same day. The expired flow rate for all
analysers was set at 50ml/s. The actual flow
rated achieved for all 3 machines was 45–55ml/s
(within 10% of the target flow rate, as recom-
mended in guidelines),6 which was verified at the
end of every reading. For the Ecomedics analyser,
the flow rate was calibrated daily. However, for the
Niox and Logan analysers calibration of the resistors
is not recommended by the manufacturers. Three
acceptable readings were recorded from each
subject using each machine, according to ATS
criteria.6
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Z. Borrill et al.1394Statistical analysis
The exhaled NO data were natural log transformed
to normalise the data. The variability of measure-
ments from the same analyser (within analyser
variability) was determined by calculating the
repeatability coefficient for each analyser.9 The
exponential of this value was then calculated. The
ratio of 2 readings from the same analyser will lie
within this exponential repeatability coefficient for
95% of subjects.
Differences between analysers were assessed by
2 methods (1) The differences between group
means were assessed using paired Student’s t-tests
and (2) the variability expected for the same
individual using the 3 analysers was estimated
using the Bland Altman method,9 which provided a
ratio and 95% limits of agreement for each pair of
analysers.0
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Within analyser variability was relatively small; the
exponential repeatability coefficients for repeated
measurements performed on 30 subjects using the
Ecomedics, Niox and Logan analysers were 1.12,
1.19 and 1.19, respectively.
Between analyser differences were assessed first
using group mean values. Measurements in the 30
subjects were significantly higher using the Logan
analyser, and lower using the Ecomedics (Fig. 1).
The same pattern was observed for lower readings
(o20 ppb) and for higher readings (420 ppb)—data
not shown. Differences between analysers for the 3
subject groups showed a consistent pattern
(Fig. 2); the Logan analyser gave significantly
higher mean values, and the Ecomedics gave
significantly lower mean values in all 3 groups.0
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Figure 1 Comparison of results obtained from the 3
analysers in all subjects (geometric mean and 95%
confidence intervals shown; #Po0.0001).
Ecomedics Niox Logan
0
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Figure 2 Comparison of analysers in the 3 subject groups
showing individual data (horizontal bars indicate geo-
metric mean values, *Po0.05, ^Po0.001, #Po0.0001).The Bland Altman method was used to quantify the
between analyser variability observed between in-
dividual measurements. The mean ratios (95% limits
of agreement) for each pair of analysers were as
follows; for Niox vs. Ecomedics 1.59 (1.02–2.50), for
Logan vs. Ecomedics 1.96 (1.09–3.57) and for Logan
vs. Niox 1.23 (0.72–2.13).
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This is the first report to compare readings from
different exhaled NO analysers. We firstly quanti-
fied within analyser variability, which was observed
to be relatively small. In contrast, significantly
greater variability was observed between analy-
sers. The group mean values provided by the Logan
analyser were significantly higher, followed in order
of magnitude by the Niox and then the Ecomedics
analyser. Our findings indicate that exhaled NO
measurements in healthy subjects and patients
with airway disease differ according to the type of
analyser used.
We firstly quantified within analyser variability
by calculating the repeatability coefficient for each
analyser. This analysis demonstrated that 95% of
repeated measurements from the same individual
can be expected to vary by up to 12% for the
Ecomedics analyser and by up to 19% for the Niox
and Logan analysers. These data can be used to
interpret the between analyser differences. It is
recognised that the measurement of a physiological
parameter from the same subject using 2 different
pieces of equipment will provide results that
differ.9 The magnitude of this difference is critical
in assessing the importance of this variability, as
small differences may be deemed clinically insig-
nificant. However, our results showed large differ-
ences between the 3 analysers studied, with the
readings from the Logan and Niox analysers being
1.96- and 1.59-fold greater, respectively, compared
to the Ecomedics analyser. Our observation that
within analyser variability was smaller than differ-
ences between analysers rules out the inherent
variability of repeated testing as an explanation for
these findings.
The remarkably consistent results observed in
asthma patients, COPD patients and healthy sub-
jects indicates that the differences between
exhaled NO analysers are independent of the
presence or type of airway disease. We recruited
mild asthma patients not taking inhaled corticos-
teroids in order to assess a homogenous group.
Similarly, we recruited a homogenous group of
COPD ex-smokers. The consistency of our results in
3 homogenous groups suggests that the differences
between analysers would also be found in other
groups, e.g. asthma patients taking inhaled corti-
costeroids or COPD patients who smoke.
Exhaled NO values above 100ppb were observed
in some asthma patients using the Logan machine.
The accuracy of these readings is not clear, as
calibration for this machine was only performed
using gas containing 100ppb NO. However, given the
similar pattern of differences between analysersobserved in healthy subjects and COPD, it is unlikely
that errors at high values in the asthma group have
significantly affected our key findings.
The reasons for our findings are unclear. The
machines were calibrated and used according to
the manufacturers’ instructions, using the recom-
mended calibration gas at the suggested concen-
tration. We deliberately used the manufacturers’
recommended calibration gases in order to repli-
cate clinical practice as closely as possible. It has
recently been reported10 that altering the calibra-
tion gas concentration used in an analyser can alter
NO measurements. However, the magnitude of
change observed was small compared to the
differences between analysers observed in the
current study. Calibration alone is therefore un-
likely to be the only reason for our findings, and we
validated the calibration procedure by ensuring
that the analysers all correctly measured 100 ppb
NO passed through the sample port. This confirmed
that the each of the analysers gave identical NO
measurements when gas from a cylinder is passed
through a sample port at 50ml/s. In contrast
exhaled human breath does not follow the
same pattern, as there were differences between
analysers. Alternatively, as exhaled NO measure-
ments are dependent on flow rate, it is possible
that the differences observed could be explained
by differences in achieved flow rates between the
analysers. However, all 3 analysers achieved the
required flow rate set at 50ml/s, which was
verified at the end of each reading. It would be
interesting to investigate whether the differences
we have observed are also present at other flow
rates.
We have shown that 3 commonly used NO
analysers give significantly different readings.
Further work is needed to clarify the reasons for
these differences, and to study differences
between other commercially available models.References
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